REFERENCES
1. Li Y, Liu Y, Liu S, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8:152.
2. Sandforth A, von Schwartzenberg RJ, Arreola EV, et al. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabetes Endocrinol. 2023;11:798-810.
3. Sandforth A, Arreola EV, Hanson RL, et al. Prevention of type 2 diabetes through prediabetes remission without weight loss. Nat Med. 2025;31:3330-40.
4. Chen L, Chen M, Yang X, et al. Energy metabolism in cardiovascular diseases: unlocking the hidden powerhouse of cardiac pathophysiology. Front Endocrinol. 2025;16:1617305.
5. Karakasis P, Stachteas P, Iliakis P, et al. Inflammation and resolution in obesity-related cardiovascular disease. Int J Mol Sci. 2026;27:535.
6. Karwi QG, Sun Q, Lopaschuk GD. The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity. Cells. 2021;10:3259.
7. Sabe SA, Feng J, Sellke FW, Abid MR. Mechanisms and clinical implications of endothelium-dependent vasomotor dysfunction in coronary microvasculature. Am J Physiol Heart Circ Physiol. 2022;322:H819-41.
8. Borg R, Cherney DZ. Glomerular hyperfiltration and tubuloglomerular feedback in diabetic kidney disease: physiological insights and potential clinical translation. J Am Soc Nephrol. 2025;36:342-4.
9. Sharma N, Verma SK, Sharma S, Kapoor N, Kalra S. Diabetic platelets: pathophysiology, clinical significance, and therapeutic perspectives. Diabetes Ther. 2025;16:2101-9.
10. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011;22:450-7.
11. Vyas V, Blythe H, Wood EG, et al. Obesity and diabetes are major risk factors for epicardial adipose tissue inflammation. JCI Insight. 2021;6:e145495.
12. Zhou Y, Yan H, Zhu Y, Jiang W, Zhang S. Multifactorial mechanisms of obesity-related HFpEF: the central role of epicardial adipose tissue and therapeutic perspectives. Front Cardiovasc Med. 2025;12:1701459.
13. Al Qassab M, Chaarani N, Hamou A, et al. The gut microbiota-insulin resistance axis: mechanisms, clinical implications, and therapeutic potential. FASEB Bioadv. 2026;8:e70080.
14. Dong H, Sun Y, Nie L, et al. Metabolic memory: mechanisms and diseases. Signal Transduct Target Ther. 2024;9:38.
15. Loomba R, Hartman ML, Lawitz EJ, et al.; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.
16. Akoumianakis I, Zagaliotis A, Konstantaraki M, Filippatos TD. GLP-1 analogs and regional adiposity: a systematic review and meta-analysis. Obes Rev. 2023;24:e13574.
17. Wang D, Morton JI, Magliano DJ, Shaw JE. Comparison of subcutaneous, visceral, liver and muscle fat depots in relation to prevalent and incident diabetes. Diabetes Obes Metab. 2025;27:6304-13.
18. Borel AL, Nazare JA, Smith J, et al. Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance. Int J Obes. 2015;39:495-501.
19. Kabahizi A, Wallace B, Lieu L, et al. Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics. Br J Pharmacol. 2022;179:600-24.
20. Lee YH, Lim S, Davies MJ. Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors. Nat Rev Endocrinol. 2025;21:783-98.
21. Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146:1882-94.
22. McGuire DK, Marx N, Mulvagh SL, et al.; SOUL Study Group. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001-12.
23. Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363.
24. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-32.
25. Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406:2257-68.
26. Nicholls SJ, Pavo I, Bhatt DL, et al.; SURPASS-CVOT Investigators. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393:2409-20.
27. Wing RR, Bolin P, Brancati FL, et al.; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145-54.
28. Carbone S, Patel KV. Semaglutide in HFpEF and obesity: targeting both for functional gains. JACC Heart Fail. 2025;13:102665.
29. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069-84.
30. Borel AL, Nazare JA, Smith J, et al. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program. Obesity. 2012;20:1223-33.
31. Ross R, Bradshaw AJ. The future of obesity reduction: beyond weight loss. Nat Rev Endocrinol. 2009;5:319-25.
32. Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13:482-93.
33. Tuleta I, Frangogiannis NG. Fibrosis of the diabetic heart: clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021;176:113904.
34. Nidorf SM, Fiolet ATL, Mosterd A, et al.; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-47.
35. Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31.
36. Agarwal R, Filippatos G, Pitt B, et al.; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84.
37. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8:e2457349.
38. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026;28:112-21.
39. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 2017;376:1943-55.
40. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14:542-59.
